Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
FRUSEMIDE
Renal · Renal · Level 1
|
SPIRONOLACTONE
Renal · Renal · Level 3
|
|---|---|---|
| Mechanism of action | Diuresis |
Acts in the DCT. |
| Physiological effects | Pulmonary and systemic vasodilation |
Sedation and muscle weakness (due to electrolyte abnm) |
| Absorption | PO/IV/SL/IM. PO BA 50% Onset PO/SL 30-60mins, IV 5 mins . |
PO - BA 70%, extensive 1st pass metb. Onset 3-4hrs, dur upto 3 days |
| Protein binding | 91-99% (Albumin) |
90% |
| Volume of distribution | 0.1L/kg |
— |
| Metabolism | Renal to glucuronide |
Hepatic: Rapidly and extensively metabolised by deacetylation and dethiolation. Active metab: canrenone and 7-alpha-spirolactone |
| Excretion | 80% unchanged in urine |
Urine and faeces |
| Half-life | 0.5-2hrs. ESRF: 9hrs |
1-2hours, metab upto 24hrs |
| Adverse Effects Toxicity | ↓ K+/Na+/Cl-/Ca++, Hyper- urea/glu/chol, Metabolic alkalosis |
↑K+(esp in renal failure). N/V and GI disturbances |
| Class Group | Diuretic - Loop |
Diuretic – Aldosterone antagonist |
| Indications Uses | Oedema of cardiac, renal or hepatic origin, Renal insufficency |
Oedema – CHF, cirrhosis with ascites, refractory. HTN, Nephrotic syndrome. With loop/thiazide to conserve K+, diagn of Conn's syndr |
| Introduction | Sulfonamide derivative |
A synthetic steroid |
| Legacy Cicm Level | Level 1 |
Level 3 |
| Presentation | Photosensitive solution 10mg/ml |
25/100mg tablets |
| Route And Dose | 20-2000mg daily |
PO. 25-200mg/day |